GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01355003

Enrollment

1080

Registered

2011-05-17

Start date

2008-02-29

Completion date

2010-06-30

Last updated

2015-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillomavirus Infections

Brief summary

This study will collect safety information on the use of GARDASIL™ in the Philippines.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

9 Years to 46 Years

Healthy volunteers

Yes

Inclusion criteria

* Received GARDASIL™

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse events following any dose of vaccine	At least 30 days following any vaccine dose

Outcome results